JP2005501010A5 - - Google Patents

Download PDF

Info

Publication number
JP2005501010A5
JP2005501010A5 JP2003503004A JP2003503004A JP2005501010A5 JP 2005501010 A5 JP2005501010 A5 JP 2005501010A5 JP 2003503004 A JP2003503004 A JP 2003503004A JP 2003503004 A JP2003503004 A JP 2003503004A JP 2005501010 A5 JP2005501010 A5 JP 2005501010A5
Authority
JP
Japan
Prior art keywords
conjugate
pept2
transporter
vmax
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003503004A
Other languages
English (en)
Japanese (ja)
Other versions
JP4342934B2 (ja
JP2005501010A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/018686 external-priority patent/WO2002100172A1/en
Publication of JP2005501010A publication Critical patent/JP2005501010A/ja
Publication of JP2005501010A5 publication Critical patent/JP2005501010A5/ja
Application granted granted Critical
Publication of JP4342934B2 publication Critical patent/JP4342934B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003503004A 2001-06-11 2002-06-11 Ｐｅｐｔ−２輸送体を介した薬剤の投与 Expired - Fee Related JP4342934B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29773201P 2001-06-11 2001-06-11
US36100202P 2002-03-01 2002-03-01
PCT/US2002/018686 WO2002100172A1 (en) 2001-06-11 2002-06-11 Administration of agents via the pept-2 transporter

Publications (3)

Publication Number Publication Date
JP2005501010A JP2005501010A (ja) 2005-01-13
JP2005501010A5 true JP2005501010A5 (https=) 2006-01-05
JP4342934B2 JP4342934B2 (ja) 2009-10-14

Family

ID=26970290

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003503004A Expired - Fee Related JP4342934B2 (ja) 2001-06-11 2002-06-11 Ｐｅｐｔ−２輸送体を介した薬剤の投与

Country Status (4)

Country Link
US (3) US6955888B2 (https=)
EP (1) EP1406493A4 (https=)
JP (1) JP4342934B2 (https=)
WO (1) WO2002100172A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6955888B2 (en) * 2001-06-11 2005-10-18 Xenoport Methods of screening agents, conjugates or conjugate moieties for transport by a PEPT2 transporter
US20030158089A1 (en) * 2002-01-24 2003-08-21 Xenoport, Inc. Administrative agents via the SMVT transporter
US20050148534A1 (en) * 2003-09-22 2005-07-07 Castellino Angelo J. Small molecule compositions and methods for increasing drug efficiency using compositions thereof
US20110008327A1 (en) 2004-03-29 2011-01-13 Cheng Jin Q Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
US20100173864A1 (en) 2004-03-29 2010-07-08 Cheng Jin Q Compositions including triciribine and one or more platinum compounds and methods of use thereof
US20100009928A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and taxanes and methods of use thereof
AU2005228410A1 (en) 2004-03-29 2005-10-13 University Of South Florida Effective treatment of tumors and cancer with triciribine and related compounds
US20100028339A1 (en) * 2004-03-29 2010-02-04 Cheng Jin Q Compositions including triciribine and trastuzumab and methods of use thereof
US20100009929A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
RU2413731C2 (ru) * 2004-04-09 2011-03-10 Чугаи Сейяку Кабусики Кайся Новые растворимые в воде пролекарства
WO2006001986A2 (en) * 2004-06-04 2006-01-05 Xenoport, Inc. Glut3 transporters expressed in cancer cells
TW200744603A (en) 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
CN1870631B (zh) * 2005-11-11 2010-04-14 华为技术有限公司 媒体网关的门控方法
WO2008052044A2 (en) * 2006-10-26 2008-05-02 Xenoport, Inc. Use of derivatives of propofol for treating diseases associated with oxidative stress
WO2009036322A1 (en) * 2007-09-14 2009-03-19 Xenoport, Inc. Use of propofol prodrugs for treating neuropathic pain
US20090118365A1 (en) * 2007-11-06 2009-05-07 Xenoport, Inc Use of Prodrugs of GABA B Agonists for Treating Neuropathic and Musculoskeletal Pain
JP2010043063A (ja) * 2008-05-09 2010-02-25 Agency For Science Technology & Research 川崎病の診断及び治療
PL3736329T3 (pl) 2012-09-11 2022-07-18 Corning Incorporated Zużywalne krioprezerwowane komórki wykazujące przejściową nadekspresję genu(-ów) kodującego(-ych) białko(-a) transportera leku i/lub enzym(y) metabolizujący(-e) lek
US20160178663A1 (en) * 2014-12-23 2016-06-23 Intel Corporation Formed wire probe interconnect for test die contactor

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2504010B1 (fr) 1981-04-15 1985-10-25 Sanofi Sa Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4590071A (en) 1984-09-25 1986-05-20 Xoma Corporation Human melanoma specific immunotoxins
US4659839A (en) 1984-10-10 1987-04-21 Mallinckrodt, Inc. Coupling agents for radiolabeled antibody fragments
EP0188256B1 (en) 1985-01-14 1991-08-21 NeoRx Metal radionuclide labeled proteins for diagnosis and therapy
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US4699784A (en) 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
WO1992009300A1 (en) 1990-11-21 1992-06-11 Iterex Pharmaceuticals Ltd. Partnership Synthesis of equimolar multiple oligomer mixtures, especially of oligopeptide mixtures
MX9200038A (es) * 1991-01-09 1992-11-01 Alza Corp Dispositivos biodegradables y composiciones para la liberacion por difusion de agentes.
JP2001524926A (ja) 1991-09-18 2001-12-04 アフィマックス テクノロジーズ ナームロゼ フェンノートシャップ オリゴマーの雑多ライブラリーの集合体を合成する方法
ES2204910T3 (es) 1992-10-01 2004-05-01 The Trustees Of Columbia University In The City Of New York Bibliotecas quimicas combinatorias complejas codificadas con señales.
IL108499A (en) 1993-02-04 2000-02-29 Lilly Co Eli Mammalian influx peptide transporter
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5565215A (en) 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
CN1134156A (zh) 1993-11-02 1996-10-23 阿菲马克斯技术公司 合成和筛选多种分子
JPH10500112A (ja) 1994-05-06 1998-01-06 ファーマコピーア，インコーポレイテッド 組合せ ジヒドロベンゾピラン ライブラリー
AU2553195A (en) 1994-05-23 1995-12-18 Arqule, Inc. Systematic modular production of aminimide- and oxazolone- based molecules having at least two structural diversity elements
US5663046A (en) 1994-06-22 1997-09-02 Pharmacopeia, Inc. Synthesis of combinatorial libraries
US5525735A (en) 1994-06-22 1996-06-11 Affymax Technologies Nv Methods for synthesizing diverse collections of pyrrolidine compounds
US7413536B1 (en) 1999-09-14 2008-08-19 Xenoport, Inc. Substrates and screening methods for transport proteins
US6955888B2 (en) 2001-06-11 2005-10-18 Xenoport Methods of screening agents, conjugates or conjugate moieties for transport by a PEPT2 transporter
US7420002B2 (en) * 2001-06-11 2008-09-02 Xenoport Amino acid conjugates providing for sustained systemic concentrations of GABA analogues

Similar Documents

Publication Publication Date Title
JP2005501010A5 (https=)
Ghosh et al. A review on new generation orodispersible tablets and its future prospective
EP1267941B1 (en) Alprazolam inclusion complexes and pharmaceutical compositions thereof
RU2147227C1 (ru) Растворяющиеся внутри ротовой полости изделия, сформованные прессованием, и способ их производства
US20090202635A1 (en) Delivery System, Application, and Method
AU772204B2 (en) Complex of ras-farnesyltransferase inhibitor and sulfobutylether-7-beta-cyclodextrin or 2-hydroxypropyl-beta-cyclodextrin and method
US20040208931A1 (en) Fast dissolving films for oral administration of drugs
JP2005529847A5 (https=)
JP2643426B2 (ja) 非経口投与用薬剤組成物
US20140275509A1 (en) Multifunctionalized materials
JP2005508332A (ja) 薬剤を送達するための、輸送タンパク質とコンジュゲートコバラミンとの同時投与
CA2426349A1 (en) Over-coated chewing gum formulations including tableted center
WO2003094886A3 (en) Desmopressin in an orodispersible dosage form
DE60001546D1 (de) Liponsaürederivate, deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
DE60023025T2 (de) 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p39-kinase-inhibitoren
PT934058E (pt) Forma estavel de medicamento para a administracao por via oral com derivados de benzimidazole como substancia activa e processo para a sua producao
JP2010520174A5 (https=)
NZ580967A (en) Composition comprising a bile salt and an effervescent excipient component for transmucosal delivery of polypeptides
ATE522513T1 (de) N-phenylarylsulfonamidverbindung, arzneimittel das diese verbindung als wirkstoff enthält, zwischenprodukt für die verbindung und verfahren zu dessen herstellung
WO2003103713A1 (ja) 速崩壊性錠剤及びその製造方法
ITMI960358A1 (it) Citochine modificate per l'uso in terapia
CA2310028A1 (en) High drug load immediate and modified release oral dosage formulations and processes for their manufacture
CN106924289A (zh) 一种含硝唑类抗菌药的复方口腔用药及其制备方法
JPWO2005084703A1 (ja) 徐放性の口腔用組成物
Schechter et al. Organ selective delivery using a tissue-directed sreptavidin-biotin system: targeting 5-fluorouridine via TNP-streptavidin